Tag Archives: Pierre-Michel Bringer

US FDA granted breakthrough therapy designation to Novartis’s BYM338 for sporadic inclusion body myositis

Designation highlights potential of BYM338 to address an unmet medical need in a serious disease If approved, BYM338 has the potential to be the first treatment for sIBM patients BYM338 is the third Novartis investigational treatment this year to receive … Read the full press release

Novartis invites 60 selected students from leading international universities to its headquarters in Switzerland for the International Biotechnology Leadership Camp

The International Biotechnology Leadership Camp (BioCamp) fosters idea exchange with leading scientists as well as entrepreneurship for young talents 60 selected students from leading international universities attend to explore science and innovation at Novartis headquarters in Basel, Switzerland Novartis CEO … Read the full press release